<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02865473</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-010915</org_study_id>
    <nct_id>NCT02865473</nct_id>
  </id_info>
  <brief_title>Anterior Segment Imaging With Ultrahigh-resolution OCT in Patients With Glaucoma and PEX - a Pilot Study</brief_title>
  <official_title>Anterior Segment Imaging With Ultrahigh-resolution OCT in Patients With Glaucoma and Pseudoexfoliation Syndrome - a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <brief_summary>
    <textblock>
      The aim of the present study is to develop a measurement protocol for optimal imaging of the&#xD;
      anterior segment of the eye, including anterior chamber angle, Schlemm's canal, filtering&#xD;
      bleb and pseudoexfoliation deposits on the lens based on measurements in patients with&#xD;
      glaucoma and PEX. In glaucoma the structures of the anterior chamber are important for&#xD;
      classification, therapy, progression and prognosis and imaging of the angle between the iris&#xD;
      and the cornea is the key for open angle and closed angle glaucoma differential diagnosis.&#xD;
      For this purpose, a customized ultrahigh resolution Spectral Domain OCT will be used to&#xD;
      validate whether the protocol can also be more widely applied in these patients. Based on the&#xD;
      obtained measurement protocol, further studies investigating anatomy and pathophysiology of&#xD;
      the anterior segment of the eye as well as surgical outcome in patients with glaucoma and PEX&#xD;
      can be planned.&#xD;
&#xD;
      The aim of the study is to develop a measurement protocol for OCT imaging and&#xD;
      characterization of the anterior chamber in glaucoma patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-dimensional imaging of the anterior eye segment</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>primary open angle glaucoma patients</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with primary angle closure</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with neovascular glaucoma</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PEX glaucoma patients</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>glaucoma patients with filtering bleb</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>instillation of antiglaucoma treatment in the study eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pilocarpine</intervention_name>
    <description>topical instillation into the study eye</description>
    <arm_group_label>healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged over 18 years&#xD;
&#xD;
        For patients with primary open angle glaucoma:&#xD;
&#xD;
          -  Diagnosed primary open angle glaucoma&#xD;
&#xD;
          -  Visual field defects and optic nerve head appearance characteristic for glaucoma&#xD;
&#xD;
          -  Open anterior chamber angle as evidenced by gonioscopy&#xD;
&#xD;
          -  No previous glaucoma surgery&#xD;
&#xD;
          -  No previous cataract surgery&#xD;
&#xD;
        For patients with primary angle closure:&#xD;
&#xD;
          -  Angle closure predisposition as evidenced from goniosocopy&#xD;
&#xD;
          -  No previous glaucoma surgery&#xD;
&#xD;
        For patients with neovascular glaucoma:&#xD;
&#xD;
        - Neovascularization in the anterior chamber angle&#xD;
&#xD;
        For patients with pseudoexfolation deposits on the lens:&#xD;
&#xD;
          -  PEX glaucoma as evidenced from slit lamp examination&#xD;
&#xD;
          -  Visual field defects and optic nerve head appearance characteristic for glaucoma&#xD;
&#xD;
          -  Open anterior chamber angle as evidenced by gonioscopy&#xD;
&#xD;
          -  No previous glaucoma or cataract surgery&#xD;
&#xD;
        For glaucoma patients with filtering bleb after trabeculectomy:&#xD;
&#xD;
          -  Patients with history of trabeculectomy secondary to open angle glaucoma in the&#xD;
             previous three months&#xD;
&#xD;
          -  No cataract surgery&#xD;
&#xD;
        For healthy volunteers:&#xD;
&#xD;
          -  No evidence of ocular disease&#xD;
&#xD;
          -  No degenerative changes in the retina in funduscopy after mydriasis&#xD;
&#xD;
          -  Ametropia less than 3 dpt.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of any abnormalities preventing reliable measurements as judged by the&#xD;
             investigator&#xD;
&#xD;
          -  Pregnancy, planned pregnancy or lactating&#xD;
&#xD;
          -  Ocular inflammation and ocular disease interfering with the study aims as judged by&#xD;
             the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gerhard Garhöfer, Assoc. Prof. PD Dr.</last_name>
    <phone>0043140400</phone>
    <phone_ext>29810</phone_ext>
    <email>gerhard.garhoefer@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Garhöfer, Assoc. Prof. PD Dr.</last_name>
      <phone>0043140400</phone>
      <phone_ext>29810</phone_ext>
      <email>gerhard.garhoefer@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Sabina Sapeta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>René Werkmeister, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Doreen Schmidl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed Bata, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Piotr Wozniak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Klemens Fondi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leopold Schmetterer, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 9, 2016</study_first_submitted>
  <study_first_submitted_qc>August 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2016</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Gerhard Garhofer</investigator_full_name>
    <investigator_title>Assoc. Prof. PD Dr.</investigator_title>
  </responsible_party>
  <keyword>Schlemm's canal lumen area</keyword>
  <keyword>PEX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pilocarpine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

